Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy

Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.Original Article